Literature DB >> 26930181

Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes.

Ling Hinshaw1, Michele Schiavon1, Vikash Dadlani1, Ashwini Mallad1, Chiara Dalla Man1, Adil Bharucha1, Rita Basu1, Jennifer R Geske1, Rickey E Carter1, Claudio Cobelli1, Ananda Basu1, Yogish C Kudva1.   

Abstract

CONTEXT: Early postprandial hyperglycemia and delayed hypoglycemia remain major problems in current management of type 1 diabetes (T1D).
OBJECTIVE: Our objective was to investigate the effects of pramlintide, known to suppress glucagon and delay gastric emptying, on postprandial glucose fluxes in T1D.
DESIGN: This was a single-center, inpatient, randomized, crossover study. PATIENTS: Twelve patients with T1D who completed the study were analyzed.
INTERVENTIONS: Subjects were studied on two occasions with or without pramlintide. Triple tracer mixed-meal method and oral minimal model were used to estimate postprandial glucose turnover and insulin sensitivity (SI). Integrated liver insulin sensitivity was calculated based on glucose turnover. Plasma glucagon and insulin were measured. MAIN OUTCOME MEASURE: Glucose turnover and SI were the main outcome measures.
RESULTS: With pramlintide, 2-hour postprandial glucose, insulin, glucagon, glucose turnover, and SI indices showed: plasma glucose excursions were reduced (difference in incremental area under the curve [iAUC], 444.0 mMmin, P = .0003); plasma insulin concentrations were lower (difference in iAUC, 7642.0 pMmin; P = .0099); plasma glucagon excursions were lower (difference in iAUC, 1730.6 pg/mlmin; P = .0147); meal rate of glucose appearance was lower (difference in iAUC: 1196.2 μM/kg fat free mass [FFM]; P = .0316), endogenous glucose production was not different (difference in iAUC: -105.5 μM/kg FFM; P = .5842), rate of glucose disappearance was lower (difference in iAUC: 1494.2 μM/kg FFM; P = .0083). SI and liver insulin sensitivity were not different between study visits (P > .05).
CONCLUSIONS: Inhibition of glucagon and gastric emptying delaying reduced 2-hour prandial glucose excursions in T1D by delaying meal rate of glucose appearance.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26930181      PMCID: PMC4870844          DOI: 10.1210/jc.2015-3952

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  Solution state structures of human pancreatic amylin and pramlintide.

Authors:  John R Cort; Zhihong Liu; Gregory M Lee; K N L Huggins; Susan Janes; Kathryn Prickett; Niels H Andersen
Journal:  Protein Eng Des Sel       Date:  2009-07-12       Impact factor: 1.650

2.  Hepatic insulin sensitivity in healthy and prediabetic subjects: from a dual- to a single-tracer oral minimal model.

Authors:  Roberto Visentin; Chiara Dalla Man; Rita Basu; Ananda Basu; Robert A Rizza; Claudio Cobelli
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-05-19       Impact factor: 4.310

Review 3.  Physiologic action of glucagon on liver glucose metabolism.

Authors:  C J Ramnanan; D S Edgerton; G Kraft; A D Cherrington
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

4.  Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?

Authors:  Meena Asmar; Michael Bache; Filip K Knop; Sten Madsbad; Jens J Holst
Journal:  J Clin Endocrinol Metab       Date:  2010-03-01       Impact factor: 5.958

5.  Analysis of the ability of pramlintide to inhibit amyloid formation by human islet amyloid polypeptide reveals a balance between optimal recognition and reduced amyloidogenicity.

Authors:  Hui Wang; Zachary Ridgway; Ping Cao; Bela Ruzsicska; Daniel P Raleigh
Journal:  Biochemistry       Date:  2015-10-30       Impact factor: 3.162

6.  Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device.

Authors:  Eda Cengiz; Stuart A Weinzimer; Jennifer L Sherr; Eileen Tichy; Melody Martin; Lori Carria; Amy Steffen; William V Tamborlane
Journal:  Pediatr Diabetes       Date:  2012-10-28       Impact factor: 4.866

7.  Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.

Authors:  Joseph J Gingell; Erica R Burns; Debbie L Hay
Journal:  Endocrinology       Date:  2013-12-20       Impact factor: 4.736

8.  Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function.

Authors:  Ling Hinshaw; Michele Schiavon; Ashwini Mallad; Chiara Dalla Man; Rita Basu; Adil E Bharucha; Claudio Cobelli; Rickey E Carter; Ananda Basu; Yogish C Kudva
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-07-29       Impact factor: 4.310

9.  Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism.

Authors:  Ananda Basu; Chiara Dalla Man; Rita Basu; Gianna Toffolo; Claudio Cobelli; Robert A Rizza
Journal:  Diabetes Care       Date:  2009-02-05       Impact factor: 19.112

10.  Diurnal pattern of insulin action in type 1 diabetes: implications for a closed-loop system.

Authors:  Ling Hinshaw; Chiara Dalla Man; Debashis K Nandy; Ahmed Saad; Adil E Bharucha; James A Levine; Robert A Rizza; Rita Basu; Rickey E Carter; Claudio Cobelli; Yogish C Kudva; Ananda Basu
Journal:  Diabetes       Date:  2013-02-27       Impact factor: 9.461

View more
  10 in total

Review 1.  Engineering biopharmaceutical formulations to improve diabetes management.

Authors:  Caitlin L Maikawa; Andrea I d'Aquino; Rayhan A Lal; Bruce A Buckingham; Eric A Appel
Journal:  Sci Transl Med       Date:  2021-01-27       Impact factor: 17.956

2.  Pramlintide for post-bariatric hypoglycaemia.

Authors:  Amanda Sheehan; Allison Goldfine; Muhammed Bajwa; Danielle Wolfs; Chisayo Kozuka; Jacqueline Piper; Kristen Fowler; Mary Elizabeth Patti
Journal:  Diabetes Obes Metab       Date:  2022-03-09       Impact factor: 6.408

3.  13C15N: glucagon-based novel isotope dilution mass spectrometry method for measurement of glucagon metabolism in humans.

Authors:  Santosh Renuse; Linda M Benson; Patrick M Vanderboom; F N U Ruchi; Yogesh R Yadav; Kenneth L Johnson; Benjamin C Brown; Jane A Peterson; Rita Basu; Daniel J McCormick; Akhilesh Pandey; Ananda Basu
Journal:  Clin Proteomics       Date:  2022-05-19       Impact factor: 5.000

4.  Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.

Authors:  Alfonso Galderisi; Jennifer Sherr; Michelle VanName; Lori Carria; Melinda Zgorski; Eileen Tichy; Kate Weyman; Eda Cengiz; Stuart Weinzimer; William Tamborlane
Journal:  J Clin Endocrinol Metab       Date:  2018-03-01       Impact factor: 5.958

Review 5.  Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development.

Authors:  Rebekah L Bower; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2016-05-18       Impact factor: 8.739

Review 6.  Diabetic Gastroparesis and Glycaemic Control.

Authors:  Ryan Jalleh; Chinmay S Marathe; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Curr Diab Rep       Date:  2019-12-02       Impact factor: 4.810

7.  Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Yong-Chao Qiao; Wei Ling; Yan-Hong Pan; Yin-Ling Chen; Dan Zhou; Yan-Mei Huang; Xiao-Xi Zhang; Hai-Lu Zhao
Journal:  Oncotarget       Date:  2017-03-08

8.  Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.

Authors:  Ananda Basu; Thomas R Pieber; Ann K Hansen; Stefanie Sach-Friedl; Lars Erichsen; Rita Basu; Hanne Haahr
Journal:  Diabetes Obes Metab       Date:  2018-03-30       Impact factor: 6.577

Review 9.  Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?

Authors:  Harriet Warnes; Rebecca Helliwell; Sam Matthew Pearson; Ramzi A Ajjan
Journal:  Diabetes Ther       Date:  2018-09-12       Impact factor: 2.945

Review 10.  What Has Bariatric Surgery Taught Us About the Role of the Upper Gastrointestinal Tract in the Regulation of Postprandial Glucose Metabolism?

Authors:  Jing Ma; Adrian Vella
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-26       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.